StockDuty ← Dashboard Sep 04, 2026 05:09 PM ET
SignalFDA/Bio

Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug

Mid-stage bladder cancer trial readout catalysts Tyra Bio's rise.

What changed
Why it matters
Mid-stage bladder cancer trial readout catalysts Tyra Bio's rise.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →